Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Resistance to anti-PD-1 Therapy in cSCC
2025-524255-32-00Phase 2Authorised
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Immunologic, genomic, and pathological correlations of response to cemiplimab in blood and tumor samples. Planned start Apr 2026; status: authorised.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2025-524255-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524255-32-00.